TrialClinical rheumatology2024

Metabolic impact of low dose IL-2 therapy for primary Sjögren's Syndrome in a double-blind, randomized clinical trial.

Ruiling Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.